ArticleJournal of gastrointestinal cancer2026
Gamma-Glutamyl Transferase Improves Biological Risk Stratification in Living Donor Liver Transplantation for Hepatocellular Carcinoma.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSerum gamma-glutamyl transferase (GGT) has been implicated as a biomarker of tumor aggressiveness across various malignancies. This study aimed to assess the utility of pre-transplant GGT in predicting post-transplant recurrence in living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC).
methodsIn this single-center retrospective cohort study, 331 patients undergoing LDLT for HCC under expanded criteria were analyzed. Descriptive statistics and Kaplan-Meier curves were used to determine association between GGT levels and recurrence free survival (RFS).
resultsWith a median follow-up of 49 months (IQR: 21–85), HCC recurred in 63 patients (19%). In multivariate analysis, GGT > 100 U/L was independently associated with increased recurrence risk (HR: 2.7; 95% CI: 1.6–4.5; P < 0.001). Elevated pre-transplant GGT (> 100 U/L) was associated with adverse tumor features, including tumor size (> 5 cm) and elevated alpha-fetoprotein (AFP) levels (both P < 0.05). MVI was more frequently observed in the high GGT group (41.0% vs. 22.2%, P < 0.001). The 5-year RFS was significantly lower in patients with high GGT (64% vs. 88%, P < 0.001). For patients in the expanded criteria, with GGT ≤ 100 U/L, 5-year RFS was not significantly different from Milan criteria (5-year RFS: 82% vs. 85%, P = 0.243). In patients with normal AFP, GGT ≤ 100 U/L identified a favorable subgroup with a 5-year RFS of 95%.
conclusionElevated pre-transplant GGT is independently associated with post-transplant recurrence in HCC patients undergoing LDLT. Integration of GGT into expanded selection criteria may improve biological risk stratification beyond conventional imaging- and AFP-based models.
Indexed as
Identifiers
41655149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.